Drugs / C14
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06672653 | Nov 2024 → Mar 2025 overdue | HIV infectious disease, cervical cancer, human papilloma virus infection, virus associated tumor | MGB Pharma | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06672653 ↗ |
| Known as | The monoterpenoid zinc tetra-ascorbo-camphorate | “The monoterpenoid zinc tetra-ascorbo-camphorate ("C14") thus possesses pleiotropic antimicrobial properties.” NCT06672653 ↗ |